“What’s in a name? That which we call a rose / By any other name would smell as sweet.” Shakespeare’s line is meant to diminish the power of labels. A rose is still a rose. Its essence does not change because someone changes the name attached to it. But in the real world, names often do more than identify. They cue associations, shape expectations, and color first impressions before the underlying thing has had a chance to speak for itself. Maybe Shakespeare was right and wrong at the same time.
Drug manufacturers correctly believe market-access decisions are primarily driven by clinical and economic considerations. Some also correctly believe that drug names can influence how patients and providers perceive a product. Yet name testing focuses on patients and providers, not on access decision makers. If drug names can subtly influence patients and providers, the relevant question is not whether their effect on access decision makers is large, but whether it is nonzero. And if that effect is not zero, then current naming research is falling short.
What drug names are supposed to do
FDA’s proprietary-name review process is focused on misbranding and medication-error risk, with an optional promotional review component as well. A proposed name cannot overstate efficacy or safety, imply an unsupported indication, or create avoidable confusion with other products. That is the official baseline: the name must be safe, non-misleading, and distinguishable in real-world use.
But manufacturers and naming consultants are plainly trying to do more than clear a regulatory bar. They are not looking for names that are merely available and safe. They are looking for names that fit the product, support its positioning, and land well with intended audiences.
Who drug names are tested with
Public descriptions of name testing appear to stop with the medication-use audience — before reaching the stakeholders who later shape access to the product. Brand Institute’s public-facing materials discuss research with providers and patients. Access decision makers are not mentioned. That omission matters. It suggests that, even when naming research goes beyond regulatory clearance and considers perception, memorability, and brand fit, it is still aimed at the medication-use audience rather than at access decision makers.
FDA materials say simulation studies should include the people involved in prescribing, transcribing, dispensing, and administering the product, and should represent the range of individuals in those workflows. That includes physicians, physician assistants, nurse practitioners, nurses, pharmacists, pharmacy technicians, ward clerks, and others as relevant. It also spans care settings such as community pharmacy, ambulatory care, hospital, and long-term care. Patients may be included in some circumstances as well.
That makes sense if the purpose is to reduce medication errors and catch confusion risks before launch. But it is not the same as testing names with access decision makers. A hospital pharmacist participating in a name-safety simulation is not the same thing as a pharmacist supporting a P&T committee. A physician participating in a simulated prescribing workflow is not the same thing as a medical director shaping medical policies.
None of this means manufacturers never test names with access decision makers. But such testing does not appear to be a standard part of the naming process.
The evidence that names shape perception
There is now direct evidence that drug names can shape perceptions. A recent experimental study found that fictitious proprietary names referring to a product’s medical indication, and names that overstated benefits, changed perceived efficacy and risk relative to neutral names. Importantly, the pattern appeared not only among consumers but also among primary care physicians. Names can influence not just lay reactions, but clinician judgments too.
Other research points in the same direction. Dohle and Siegrist found that drug names with lower processing fluency — that is, names that were harder to read or pronounce — were perceived as more hazardous and reduced willingness to buy. The point is that the way a name is processed can change how the product is received.
Sound symbolism research adds another layer. Park, et al. found that voiced consonants in pharmaceutical brand names increased expectations of potency, long-lasting efficacy, price, and potential side effects. In other words, even the sounds inside a name can cue expectations about what kind of product this is and how serious, strong, or consequential it seems. Names are not inert. They carry signals.
The missed market-access opportunity
If a name can shape how patients and providers perceive a product, then it is at least plausible that it could also shape how access decision makers perceive it. In a close formulary or medical policy decision, even a small perceptual effect can matter. This is not to say that names dominate formulary or medical policy decisions. That would overstate the case.
It means something narrower. A name may shape the first layer of reaction before a product’s clinical and economic attributes are fully debated: whether it sounds serious or gimmicky, evidence-based or promotional, familiar or unfamiliar. Those early impressions may subtly influence how the product is framed and discussed by access decision makers.
Adding a small amount of testing with access decision makers to an existing naming program would be inexpensive relative to the broader cost of launch planning. If that testing helped identify a name that made a better impression on access decision makers, even a small effect could justify the cost.
So, what is in a name? Not everything. A weak product does not become strong because it is well named. Shakespeare was right about that. But neither is a name nothing. Roses may still smell sweet by any other name, yet in pharmaceuticals, names can change what access decision makers expect before they ever evaluate the product’s clinical and economic attributes. Perhaps that is where Shakespeare’s line stops being true in practice — and where most brand teams still underestimate what a name can do.
No Comments